Adibkia, Khosro, Omidi, Yadollah, Javadzadeh, Ali R., Barzegar-Jalali, Mohammad, Barar, Jaleh, Maleki, Nasrin, Mohammadi, Ghobad, Nokhodchi, Ali (2007) Inhibition of Endotoxin-Induced Uveitis by Methylprednisolone Acetate Nanosuspension in rabbits. Journal of Ocular Pharmacology and Therapeutics, 23 (5). pp. 421-432. ISSN 1080-7683. (doi:10.1089/jop.2007.0039) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided) (KAR id:10060)
The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. | |
Official URL: http://dx.doi.org/10.1089/jop.2007.0039 |
Abstract
Purpose: In the current investigation, nanoformulations of methylprednisolone acetate(MPA) were formulated using Eudragit®RS100 to study their impacts on inhibition of
inflammatory symptoms in rabbits with endotoxin-induced uveitis (EIU).Methods: A modified quasi-emulsion solvent diffusion (QESD) technique was used for preparation of nanoparticles. The drug release profiles and physicochemical characteristics of the nanoformulations were studied by means of the X-ray crystallography, differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FT-IR). Particle size analysis yielded mean diameter of approximately 380, 460 and 580 (nm) for MPA-Eudragit®RS100 nanoparticles at the ratios of 1:2.5, 1:5 and 1:10, respectively. Major clinical symptoms of EIU (morphological changes, leukocytes numbers and protein levels within the aqueous humor) were examined.
Results: Upon the physicochemical characterizations, no crystal changes or chemical interactions were observed for MPA-Eudragit®RS100 nanoparticles. The 1:2.5 ratio of
drug-polymer resulted in the most controlled release of MPA. The in vivo examinations revealed that the endotoxin induced inflammation can be inhibited by the MPA-Eudragit®
RS100 nanosuspension more significantly than the microsuspension of MPA itself in the rabbits with EIU.
Conclusion: Based on our findings, we suggest that the MPA-Eudragit®RS100 nanosuspension may favor the localized controlled ocular delivery of MPA for prevention of inflammatory symptoms in ocular diseases.
Item Type: | Article |
---|---|
DOI/Identification number: | 10.1089/jop.2007.0039 |
Subjects: | Q Science |
Divisions: | Divisions > Division of Natural Sciences > Medway School of Pharmacy |
Depositing User: | Ali Nokhodchi |
Date Deposited: | 10 Jul 2008 12:44 UTC |
Last Modified: | 05 Nov 2024 09:43 UTC |
Resource URI: | https://kar.kent.ac.uk/id/eprint/10060 (The current URI for this page, for reference purposes) |
- Export to:
- RefWorks
- EPrints3 XML
- BibTeX
- CSV
- Depositors only (login required):